Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Eton Pharmaceuticals (NASDAQ:ETON) posted its earnings results on Thursday. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.31 by $0.19, FiscalAI reports. The business had revenue of $57.93 million during the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a return on equity of 144.74% and a net margin of 35.35%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Eton reported record third-quarter revenue of $57.9 million, up 158% year over year, with growth from HEMANGEOL and strength across its portfolio. The company raised 2026 revenue guidance to more than $175 million.
• Profitability and cash generation improved sharply: adjusted gross margin was 80%, adjusted EBITDA was $28.5 million (49% of revenue), and cash from operations was $35 million. Eton ended the quarter with $55.6 million in cash after a $5 million debt prepayment, and now expects a full-year adjusted EBITDA margin above 40%.
• LIBERVANT adds a potential near-term growth driver in seizure-cluster treatment; Eton expects to launch in April 2027, subject to FDA approval and resolution of exclusivity restrictions. Management sees opportunity for its portable buccal film in a U.S. market it estimates exceeds $450 million annually.
• Management sees significant pipeline upside, particularly from ASN-001, a topical hemangioma treatment it believes could serve a broader population than HEMANGEOL; a short bioavailability study is underway, with an NDA submission targeted for mid-2027 and a potential 2028 launch. Other programs include a planned 2027 study of ET-900 for infantile spasms and a potential 2027 launch for glibenclamide oral suspension.
• ET-700’s proof-of-concept study found treatment-related adverse events in 1 of 12 participants versus 8 of 12 on GALZIN, but it blocked copper absorption less effectively than GALZIN. Eton attributed the efficacy gap to a release profile it says was too slow and plans to test faster-release formulations in 2027, leaving the program’s next steps dependent on further results.

Eton Pharmaceuticals Price Performance

Shares of ETON traded up $9.31 during mid-day trading on Friday, hitting $56.46. 1,269,987 shares of the company traded hands, compared to its average volume of 415,837. The business has a 50-day moving average of $54.80 and a 200 day moving average of $36.46. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $66.37. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 37.39 and a beta of 0.89.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director directly owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Krempa sold 25,000 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the sale, the insider directly owned 37,025 shares of the company’s stock, valued at $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 79,166 shares of company stock worth $4,809,672 over the last quarter. Corporate insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Analyst Ratings Changes

Several research firms have issued reports on ETON. HC Wainwright increased their price objective on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday. Craig Hallum reiterated a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. B. Riley Financial reissued a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Finally, Canaccord Genuity Group increased their price target on Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Eton Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $77.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.